ARQT News & Events

Reports Q1 revenue $105.4M, consensus $103.66M. "Strong product revenue in the first quarter was driven by continued robust demand for ZORYVE, which remains the leading prescribed branded topical across its three approved indications. During the quarter, we also advanced our pipeline with the initiation of a Phase 1 trial for ARQ-234, our biologic candidate for atopic dermatitis, submission of an sNDA to the FDA to expand the ZORYVE cream indication in atopic dermatitis to patients as young as 3 months, and progress on our Phase 2 proof-of-concept studies of ZORYVE in potential new indications," said Frank Watanabe, president and chief executive officer. "We also continued to generate positive cash flow, underscoring our focus on financial and operational discipline as we continue to advance our corporate strategy."

The company said, "The Company continues to anticipate net product revenue of between $480 million and $495 million for the full year 2026."

Arcutis Biotherapeutics announced the submission of a supplemental new drug application to the FDA seeking to expand the indication for Zoryve cream 0.05% to include the topical treatment of mild to moderate atopic dermatitis in infants down to three months.